Sola Failures Appears 'Near-Perfect' for Biogen (BIIB) - Stifel
- Dollar lower, stocks flat as caution creeps in ahead of Trump inauguration
- General Electric (GE) Reports In-Line Q4 EPS
- IBM (IBM) Tops Q4 EPS by 13c, FY17 EPS Guidance Beats Consensus
- American Express (AXP) Misses Q4 EPS by 7c, FY17 EPS Guidance Tops Views at Mid-Poinit
- Skyworks Solutions (SWKS) Tops Q1 EPS by 3c, Offers Q2 Guidance, Announces Buyback
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Stifel analyst Thomas Shrader weighed in on Biogen (NASDAQ: BIIB) Eli Lilly's Solanezumab did not meet its primary endpoint in the EXPEDITION3 clinical trial. Solanezumab's near-miss is near-Perfect for Biogen, Shrader said.
Shrader commented, "Solanezumab did not meet its primary endpoint in the EXPEDITION3 clinical trial, a result we fully expected for an antibody that principally binds the wrong form of A-beta plaque in a trial that chased a signal in more advanced patients. The final P-value of 0.095 and directionally positive secondary endpoints seem too far from significance for the drug to be approved by even the most lenient of FDA and Lilly reported there will not be a regulatory submission. This situation seems ideal for Biogen and the aducanumab development story which we view as focused on a better antibody in a more appropriate population. Going forward, the only competition for aducanumab is likely to come from the BACE inhibitors (Merck and Biogen / Eisai) and RAGE inhibitors (vTv therapeutics) – if these molecules are safe and efficacious (several pivotal trials are ongoing)."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB): Tecfidera Sales Could Be Weak - Baird
- Goldman Sachs Downgrades Equifax (EFX) to Sell
- Checkpoint Software (CHKP) PT Raised to $105 at Instinet
Create E-mail Alert Related CategoriesAnalyst Comments, FDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!